Colleen Kusy
Stock Analyst at Baird
(3.62)
# 3,380
Out of 5,182 analysts
53
Total ratings
42.55%
Success rate
10.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Maintains: Outperform | $65 → $90 | $69.24 | +29.98% | 3 | Apr 14, 2026 | |
| CLYM Climb Bio | Maintains: Outperform | $9 → $12 | $9.02 | +33.04% | 2 | Mar 6, 2026 | |
| ARGX argenx SE | Maintains: Neutral | $858 → $867 | $788.13 | +10.01% | 2 | Feb 27, 2026 | |
| NUVL Nuvalent | Maintains: Outperform | $112 → $158 | $108.02 | +46.27% | 3 | Nov 18, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $14 → $34 | $36.14 | -5.92% | 1 | Nov 11, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $50 → $52 | $40.94 | +27.02% | 13 | Oct 31, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $17 → $24 | $9.59 | +150.26% | 5 | Oct 3, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $40 → $52 | $43.89 | +18.48% | 3 | Jun 16, 2025 | |
| AGEN Agenus | Maintains: Neutral | $4 → $6 | $3.76 | +59.57% | 4 | Jun 4, 2025 | |
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $26.77 | +53.16% | 4 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $6 | $1.76 | +240.91% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $27 → $25 | $10.43 | +139.69% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $8.75 | +2,300.00% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $3.48 | +877.01% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $3.80 | +5,952.63% | 1 | Nov 2, 2021 |
Spyre Therapeutics
Apr 14, 2026
Maintains: Outperform
Price Target: $65 → $90
Current: $69.24
Upside: +29.98%
Climb Bio
Mar 6, 2026
Maintains: Outperform
Price Target: $9 → $12
Current: $9.02
Upside: +33.04%
argenx SE
Feb 27, 2026
Maintains: Neutral
Price Target: $858 → $867
Current: $788.13
Upside: +10.01%
Nuvalent
Nov 18, 2025
Maintains: Outperform
Price Target: $112 → $158
Current: $108.02
Upside: +46.27%
Cogent Biosciences
Nov 11, 2025
Maintains: Neutral
Price Target: $14 → $34
Current: $36.14
Upside: -5.92%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Outperform
Price Target: $50 → $52
Current: $40.94
Upside: +27.02%
Ocular Therapeutix
Oct 3, 2025
Maintains: Outperform
Price Target: $17 → $24
Current: $9.59
Upside: +150.26%
Enliven Therapeutics
Jun 16, 2025
Maintains: Outperform
Price Target: $40 → $52
Current: $43.89
Upside: +18.48%
Agenus
Jun 4, 2025
Maintains: Neutral
Price Target: $4 → $6
Current: $3.76
Upside: +59.57%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $26.77
Upside: +53.16%
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $1.76
Upside: +240.91%
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $10.43
Upside: +139.69%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $8.75
Upside: +2,300.00%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $3.48
Upside: +877.01%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $3.80
Upside: +5,952.63%